Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Almagate→

Almagate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
66827-12-1
Molecular formula
CH11AlMg3O12
Molecular weight
314.99 g/mol
Drug class
Aluminium-magnesium antacid complex
Mechanism of action
Neutralises gastric hydrochloric acid through acid-base reactions involving aluminium and magnesium hydroxide components, increasing gastric pH and reducing acid-related symptoms.
Indications / reported uses
  • Symptomatic relief of heartburn, acid indigestion and dyspepsia in countries where almagate-containing oral antacid products are authorised

Sources: NLM MeSH — Almagate · PubMed — Almagate antacid pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Almagate Environmental Risk Assessment (ERA) (the Almagate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.